Literature DB >> 2889215

Current concept for improving treatment of prostate cancer based on combination of LH-RH agonists with other agents.

A V Schally1, T W Redding, J I Paz-Bouza, A M Comaru-Schally, G Mathe.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1987        PMID： 2889215

Source DB:  PubMed          Journal:  Prog Clin Biol Res        ISSN： 0361-7742


× No keyword cloud information.
  3 in total

1.  Receptors for prolactin, somatostatin, and luteinizing hormone-releasing hormone in experimental prostate cancer after treatment with analogs of luteinizing hormone-releasing hormone and somatostatin.

Authors:  T Kadar; T W Redding; M Ben-David; A V Schally
Journal:  Proc Natl Acad Sci U S A       Date:  1988-02       Impact factor: 11.205

2.  Inhibition of growth of human mammary tumor cells by potent antagonists of luteinizing hormone-releasing hormone.

Authors:  Y Sharoni; E Bosin; A Miinster; J Levy; A V Schally
Journal:  Proc Natl Acad Sci U S A       Date:  1989-03       Impact factor: 11.205

3.  Inhibition of growth of experimental prostate cancer with sustained delivery systems (microcapsules and microgranules) of the luteinizing hormone-releasing hormone antagonist SB-75.

Authors:  E Korkut; L Bokser; A M Comaru-Schally; K Groot; A V Schally
Journal:  Proc Natl Acad Sci U S A       Date:  1991-02-01       Impact factor: 11.205
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.